XencorXNCR
XNCR
About: Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Employees: 250
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
85% more call options, than puts
Call options by funds: $37K | Put options by funds: $20K
44% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 25
5% more funds holding
Funds holding: 192 [Q4 2024] → 201 (+9) [Q1 2025]
4.44% more ownership
Funds ownership: 107.12% [Q4 2024] → 111.56% (+4.44%) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 64
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
51% less capital invested
Capital invested by funds: $1.72B [Q4 2024] → $836M (-$887M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$6
35%
downside
Avg. target
$6
35%
downside
High target
$6
35%
downside
1 analyst rating
0 positive
0%
0 neutral
0%
1 negative
100%
Barclays Peter Lawson | 35%downside $6 | Underweight Maintained | 8 May 2025 |
Financial journalist opinion
Negative
Zacks Investment Research
1 month ago
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago.
Neutral
Business Wire
1 month ago
Xencor Reports First Quarter 2025 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. “Recently presented interim Phase 1 results support XmAb942 as a high potency investigational anti-TL1A antibody and an every 12-week subcutaneous dosing regimen during.
Negative
Zacks Investment Research
1 month ago
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
1 month ago
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Interim results fro.
Positive
Zacks Investment Research
2 months ago
Xencor (XNCR) Upgraded to Buy: Here's Why
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Business Wire
3 months ago
Xencor Appoints Todd Simpson to Board of Directors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023.
Negative
Zacks Investment Research
3 months ago
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.31 per share a year ago.
Neutral
Business Wire
3 months ago
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided clinical updates and priorities for 2025. “In 2024, we began rebalancing our pipeline to focus on XmAb® drug candidates that leverage our protein engineering strengths and reduce exposure to biologica.
Positive
Market Watch
3 months ago
20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'
The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries.
Neutral
Zacks Investment Research
4 months ago
Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Charts implemented using Lightweight Charts™